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Abstract: MUC1 is expressed on the apical surface of glandular epithelium. With functions including protection, adhesion 
and signaling, MUC1 has been implicated in prostate cancer. There are many splice variants, the best characterized of which 
are MUC1/1 and MUC1/2 which are determined by a SNP (rs4072037, 3506GA).
Blood DNA from the general population, BPH, sporadic and hereditary prostate cancer subjects were genotyped for the 
rs4072037 SNP. G allele frequencies were signifi cantly reduced in hereditary prostate cancer (15%) compared to population, 
BPH or sporadic prostate cancer samples (27%, 39% and 26% respectively). In addition, the G allele was lost from 3 of 8 
heterozygous sporadic prostate tumor samples compared to matched blood DNA. Bioinformatics analysis of MUC1 protein 
sequences provides insight into differences between the variants which may be functionally relevant. The literature indicates 
discrepancies between immuno-histochemical studies, possibly due to the variety of MUC1 epitopes targeting diverse 
regions of the molecule. The contradictory fi ndings in cell lines highlight the problem associated with inadequate experimental 
systems.
This is the fi rst report of genetic differences in MUC1 between blood and prostatic cancer tissue. This fi nding is important 
as proof of principle, given that many association studies focus on blood DNA rather than on the tumor DNA. As yet, 
potential functional differences between splice variants has been paid little attention. Antibodies which discriminate between 
the variants and standardization of methods would help to clarify whether there is a role for MUC1 as a prognostic 
marker.
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Introduction
Mucin 1 (MUC1, also designated CD227, EMA, H23AG, MAM6, PEM, PEMT or PUM) is a large 
type I glycoprotein. Classically defi ned by the presence of an extensive variable number tandem repeat 
(VNTR), MUC1 moieties vary in size. Modifi cations, such as phosphorylation or glycosylation, are 
frequent on both the core protein and on the VNTR (Obermair et al. 2002). Indeed it is proposed that 
each repeat may have 5 glycosyl side chains added (Obermair et al. 2002). MUC1 is both a transmem-
brane and a secreted protein and it’s expression is restricted to the apical surface of glandular epithelium 
(Arai et al. 2005). MUC1 has roles in adhesion, protection from mechanical stress and bacterial infec-
tion, hydration and mucus production, immuno-supression and cellular signaling (Macao et al. 2006). 
Altered expression levels and localization, as well as delayed tumor formation being observed in knock-
out mice (Baruch et al. 1997), implicate MUC1 in cancers such as prostate cancer.
Processing of MUC1 proteins can result in both secreted and membrane-tethered variants, as dem-
onstrated in Figure 1. The manner by which MUC1 undergoes cleavage has recently been described 
(Levitin et al. 2005; Palmai-Pallag et al. 2005; Macao et al. 2006), in which an enterokinase and agrin 
domain found in sea urchin sperm protein (SEA domain) generates the two polypeptides, MUC1-N and 
MUC1-C (Macao et al. 2006). The extra cellular fragment (MUC1-N) remains at the cell membrane 
by forming hetero-dimers with the transmembrane fragment (MUC1-C) (Palmai-Pallag et al. 2005). 
The functions of MUC1 are likely to depend upon the length and modifi cations of MUC1-N, as well 
as the localization and binding partners of MUC1-C.
There are as many as 9 different MUC1 variants (according to the SwissProt database, see Figure 2 
for schematic presentation of variants), with varying degrees of post-translational modifi cations (PTMs). 
Functional differences or tissue-specifi c distribution of the variants have not been conclusively proven. 
The general format for identifying these proteins is MUC1/isoform name or number, for example 
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MUC1/1 denotes MUC1 isoform 1. Variants may 
result from alternative splicing or genetic varia-
tions. The two best characterized variants, MUC1/1 
or B (3506A) and MUC1/2 or A (3506G), are 
determined by a single nucleotide polymorphism 
(SNP) (rs4072037 (2005)) (Obermair et al. 2002) 
of MUC1 (chromosome 1q21). The variant allele 
(i.e. the least common) causes formation of a novel 
splice acceptor site (Ligtenberg et al. 1991) intro-
ducing an extra stretch of nucleotides between 
exons 1 and 2 of the mRNA, thus gives rise to 
MUC1/1 which encodes 9 amino acids not present 
in MUC1/2 (Ligtenberg et al. 1991). This SNP 
(G3506A, GeneBank Accession number NT_
079484.1) is also associated, by linkage disequi-
librium, with the length of the VNTR (Baruch et al. 
1997). Differential expression of MUC1 variants, 
including MUC1/1 and MUC1/2, has been noted 
previously in ovarian (Obermair et al. 2002) and 
breast (Schmid et al. 2002) cancers.
1
2
3
4
10
11
12
Nucleus
Cytoplasm
5
6
7
8
ER
Golgi
7
9
Basement membrane LumenEpithelium
Figure 1. A schematic representation of MUC1 processing, adapted from (Julian et al. 2002; Engelmann et al. 2005; Levitin et al. 2005). 1) 
Transcription of MUC1 gene. 2) Translation of immature MUC1 protein. 3) Maturation of the initial MUC1 protein. 4) Traffi cking of mature 
MUC1 into the ER. 5) Primary cleavage and dimerization. White fragments correspond to MUC1-N while black fragments correspond to 
MUC1-C. 6) Transport to golgi for post translational modifi cations i.e. glycosylation. 7) Traffi cking to cell surface. 8) Recycling to golgi via 
clatherin-mediated endocytosis. 9) Post translational modifi cations i.e. sialylation. 10) Secondary cleavage releasing extra cellular component 
into intercellular space. 11) Signaling. 12) Endocytosis and recycling or degradation.
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The potential role of MUC1 in prostate cancer 
has been studied extensively. However, develop-
ment of MUC1 as a biomarker for presence or 
progression of prostate cancer has been hindered 
by confl icting reports. This report provides exper-
imental evidence of a reduced G allele frequency 
in hereditary prostate cancer as well as loss of 
heterozygocity (LOH) of MUC1 in prostate tumor 
DNA compared to matched blood DNA. In addi-
tion, in silico comparison of protein sequences and 
motifs and thus analysis of possible isoform dif-
ferences is summarized.
Materials and Methods
DNA samples
Samples were collected for a previous study and 
genomic DNA extracted from blood as previously 
described (Li et al. 1999). 199 blood DNA samples 
were analyzed, including 46 from sporadic and 51 
from hereditary prostate cancer patients, 35 from 
benign prostatic hyperplasia (BPH) patients and 
67 from healthy young men (population sample). 
Of the 46 sporadic prostate cancer patients, 22 also 
had DNA samples extracted from prostate cancer 
tissues, forming 22 pairs of matched normal and 
tumor DNA samples. The baseline characteristics 
of all subjects are described in Table 1. The popu-
lation samples were collected anonymously from 
healthy young men (age about 20 years) entering 
military service in the north of Sweden. Hereditary 
prostate cancer samples were collected from the 
same region, while BPH and sporadic prostate 
cancer samples were collected from, and thus are 
representative of, the greater Stockholm region. 
All samples were from Swedish subjects. The 
Swedish population is rather homogeneous, with 
approximately 85% being Caucasian. BPH patients 
were selected at random, but sporadic prostate 
cancer patients were selected due to large tumor 
size. All samples had matching slides, which were 
reviewed and diagnosis confi rmed by a single 
pathologist at each centre. BPH samples represent 
a specifi c subset of the population which is very 
unlikely to subsequently develop prostate cancer, 
given the average age of 79 years. All BPH patients 
had histopathological examination of transurethral 
resection specimen to exclude possible incidental 
prostate cancer, in addition to measurement of 
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Figure 2. Schematic diagram of the 9 set a MUC1 variants. Solid black, transmembrane domain; pale grey, juxta-membrane extra cellular 
region; white, cytoplasmic region; dark grey, N terminal domain; solid line, VNTR; fl ash, SEA cleavage motif; arrow, SNP rs4072037; gradient 
grey, unique sequences; triangles (all), phosphorylation sites; cross, β catenin binding site; dotted area 9 amino acids unique to MUC1/2; 
X, signal peptide; arrow, exon 2 SNP.
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serum prostate specifi c antigen (all within the 
normal range) and other clinical examinations 
(including ultrasound and digital rectal examination) 
without signs of prostate cancer. Hereditary pros-
tate cancer is here defi ned as a patient having at 
least 2 fi rst degree relatives with clinically and 
pathologically confi rmed prostate cancer (Smith 
et al. 1996). Ethical permission from Karolinska 
Institutet and Umeå University has been granted.
MUC1 SNP genotyping
Based on the human MUC1 genomic sequence 
(GeneBank accession number: NT_079484.1), we 
designed 2 primer pairs to carry out a nested PCR 
according to a standard PCR protocol using a 
Platinum Taq DNA polymerase (Invitrogen). Ther-
mocycling parameters were set as follows: initial 
denaturing at 94 °C for 2 min; 30 cycles each of 
which at 94 °C for 30 sec, 53 °C for 45 sec, 74 °C 
for 45 sec; and a fi nal extension at 74 °C for 5 min. 
The size of PCR product was confi rmed by agarose 
gel electrophoresis, before being purifi ed using a 
Qiaquick PCR purifi cation kit (Qiagen) and quan-
tifi ed by photo spectrometry. A sequencing reaction 
was carried out using a sequencing primer on the 
reverse strand with a Beckman Coulter DTCS 
quick start kit in accordance with manufacturer’s 
instructions. Primer sequences are available upon 
request. Beckman Coulter’s CEQ™ 8000 Genetic 
Analysis System was used for sequence analysis. 
Quality control of sample processing was achieved 
by a single researcher performing all reactions, 
with a single protocol and kit. A random selection 
of samples was repeated to confi rm results and 
accuracy. No clinical data was available to the 
researcher prior to genotype calling of these 
samples, thus preventing any bias. Sequence chro-
matograms were very clear (Fig. 2) and genotype 
calling was carried out by two independent 
researchers to confi rm analysis.
Statistical analysis
To determine whether specifi c alleles were associ-
ated with BPH or prostate cancer, comparisons 
were drawn on allele frequencies between sample 
sets using the Chi2 test, with the null hypothesis 
assuming that there is no signifi cant difference 
between allele frequencies of each sample set.
LOH analysis
Using the Beckman Coulter’s CEQ™ 8000 Genetic 
Analysis System, LOH analysis was carried out on 
sporadic prostate cancer samples by comparing the 
genotype of rs4072037 in blood DNA with tumor 
DNA from the same patient. Parameters for this 
analysis were set as follows: Percentage over peak 
spacing 70%; height ratio 30%; sensitivity 25%.
In silico protein sequence analysis
MUC1 protein sequences (NCBI P15941, 
P15941-2, P15941-3, P15941-4, P15941-5, 
P15941-6, P15941-7, P15941-8 and P15941-9) 
were identified from the SwissProt database 
(Boeckmann et al. 2005), and (330608, 338983, 
343482, 342814, 339690, 357374, 357375, 
357377, 357378, 357580, 357381, 357383, all 
prefi xed with ESNP00000) the Human Protein 
Atlas (Uhlen, 2007), and compared using cluster 
software T-coffee version 1 (Notredame et al. 
Table 1. Clinical characteristics of sample sets.
    Population BPH SPC HPC
n  67 35 46 51
Age (years) Mean age  20 79 69 67
 sd   3.8 8.4 8.4
Stage Localized    28 27
 Advanced    30 15
 Metastatic    6 0
 (n)    46 42
Grade Grade 1     9 14
 Grade 2    14 0
 Grade 3    22 31
 (n)     45 45
BPH benign prostatic hyperplasia SPC sporadic prostate cancer; HPC hereditary prostate cancer; Localized Stage T1-2 Advanced T3-4, 
Metastatic TxN1Mx or TxNxM1; grading as per WHO, where 1 well differentiated (approximately Gleason grade 2–6), 2 medium differentia-
tion (approximately Gleason grade 7), 3 poorly differentiated (approximately Gleason grade 8–10).
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2000) and Blast 2 (via NCBI website). Conserved 
motif sequences previously reported in literature 
(Palmai-Pallag et al. 2005; Kinlough et al. 2006) 
were manually identifi ed in the protein sequences. 
Potential protein motifs were identifi ed using 
SMART (Ponting et al. 1999) and MyHits motif 
scan platform (Falquet et al. 2002). The presence 
of signal peptides was assessed using the SignalP 
3.0 platform (Bendtsen et al. 2004). PPSearch, 
via the EBI website, was used to detect potential 
protein motifs. The isoelectric point and molecu-
lar mass of the MUC1 protein variants were 
predicted using the Compute pI/Mw (Gasteiger 
et al. 2003) program.
Results
Experimental data
Disease association
MUC1 exon 2 (3506G/A) genotype frequencies in 
blood DNA samples only demonstrated signifi cant 
differences (Table 2) when BPH and hereditary 
prostate cancer samples were compared. In con-
trast, allele frequencies were signifi cantly different 
when hereditary prostate cancer (15% G allele) 
samples where compared to the population (27% 
G allele), BPH (40% G allele) or sporadic prostate 
cancer samples (27% G allele). Hereditary prostate 
cancer samples may be enriched for certain genetic 
variations, due to inclusion of multiple members 
of some families. When only one member of each 
hereditary prostate cancer family was included, 
signifi cance still remained when compared to BPH 
samples, for both genotype and allele frequencies. 
That the signifi cance was lost in some comparisons 
(hereditary prostate cancer vs. population and 
sporadic prostate cancer) may be due to the small 
number of G alleles present (n = 9).
Comparison between blood 
and tumor samples
8 of 22 pairs of normal and tumor DNA samples 
were G/A heterozygous in blood DNA samples. Of 
these 8 heterozygous patients, LOH could be clearly 
identifi ed in 3 of the tumor DNA samples, with the 
G allele consistently being lost (Figure 3). Most 
DNA samples with matching tumour samples were 
of high Gleason grade, but this did not appear to 
differ much between genotypes (average for CC 8.5, Ta
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TC 7, TT 7.9). There appeared to be no correlation 
between LOH and grade of tumour or age.
Bioinformatics analysis of protein 
sequences
Variants
Table 3 provides a summary of differences between 
the MUC1 variants, including both described and 
bioinformatically predicted variants. There is a 
large degree of overlap between the different 
MUC1 variants and motifs, as shown schematically 
for the SwissProt variants (set a) in Figure 2. 
Another database, the Human Protein Atlas (HPA), 
lists 12 variants (set b). 4 of the SwissProt variants 
(6, 7, 8 and 9) share 99% homology with 4 of those 
listed by the HPA (19, 12, 3 and 17 respectively). 
Interestingly, with all 4 of these pairs, the one 
amino acid difference is the 4th from last amino 
acid, which in set a is alanine, but in set b is 
theonine. In addition, of the 12 variants in set b, 
only 2 contain a VNTR (2 and 16), and Blast2 
analysis demonstrates 100% homology between 
these two variants.
Most variants share a similar primary structure, 
consisting of a signal peptide, an extra cellular 
domain, a transmembrane domain and a cytosolic 
domain. The N-terminal domains vary in length, 
however sequence alignment indicates that a 
stretch of 51 amino acids of the N terminal 
is common to all variants (Fig. 4a). MUC1/4 
(set a) lacks a further 10 amino acids which 
are present in all other variants. Only variants 
9 (set a), 11 and 17 (set b) lack a transmembrane 
domain. MUC1-C is also well conserved (Fig. 4b), 
with a stretch of 74 amino acids present in all but 
variants 5 (both sets). An adjacent stretch of 30 
amino acids is common to all except variants 9 
(set a), 11 and 17 (set b). The isoform sequences 
then become more divergent. Of note, both 
variants 5 (both sets) appear to be distinct from 
the other variants; they contain the N terminal 
consensus sequence, but at the C terminal share 
a stretch of only 23 amino acids, which contain 
no predicted domains. MUC1/5, 9 (set a) and 17 
(set b) have two regions of 100% homology; the 
N terminal domain 54 residues, including the 
signal peptide and a stretch of 42 amino acids in 
the C terminal region.
Figure 3. Chromatograms of blood (D2N) and tumor (D2T) samples from a prostate cancer patient. The MUC1 SNP site and its LOH in the 
tumor are indicated by an arrow at the corresponding base. Y indicates presence of both C and T alleles. Note that this is the reverse strand 
of DNA thus C and T correspond to G and A (respectively) on the forward strand.
D2N
D2T
309
MUC1, a biomarker for prostate cancer
Biomarker Insights 2008:3 
Ta
bl
e 
3.
 P
re
di
ct
ed
 fu
nc
tio
ns
, c
ha
ra
ct
er
is
tic
s 
an
d 
si
te
s 
of
 p
os
t t
ra
ns
la
tio
na
l m
od
ifi 
ca
tio
ns
 o
f M
U
C
1 
va
ria
nt
s.
W
he
re
 s
pl
ic
e 
va
ria
nt
s 
ar
e 
fro
m
 a
 S
w
is
sP
ro
t, 
b 
H
um
an
 P
ro
te
in
 A
tla
s.
 T
M
 tr
an
sm
em
br
an
e 
do
m
ai
n,
 V
N
TR
 v
ar
ia
bl
e 
nu
m
be
r t
an
de
m
 re
pe
at
, M
w
 m
ol
ec
ul
ar
 w
ei
gh
t, 
pI
 is
oe
le
ct
ric
 p
oi
nt
, 
P
K
C
 p
ro
te
in
 k
in
as
e 
C
, C
K
2 
ca
se
in
 k
in
as
e 
2,
 P
a 
pa
lm
ity
la
tio
n,
 >
 e
xt
ra
 a
m
in
o 
ac
id
s 
(c
om
pa
re
d 
to
 M
U
C
1/
1)
, <
 lo
ss
 o
f a
m
in
o 
ac
id
s,
 ¤
 p
ot
en
tia
l t
o 
ac
t a
s 
a 
re
ce
pt
or
 o
r l
ig
an
d,
 *
 m
os
t l
ik
el
y 
in
 th
e 
V
N
TR
.
P
a
SAR*
STK*
TDR
TQR
TEK
TTK
SCR
SSTE
SAPD*
TKTD*
SSTD
SPYE
SSLE
SLED
SVSD
TISD
TGGE
SCRE
NASG
NVTS*
NGTS*
NHST*
NSSL
NLTI
GSGHAS
GVFNAS
GSAATW*
GSASGS*
GSASTL*
GQDVTS*
GQDVTL*
GSSTTQ*
GSGSST*
GNGGSS
GSSLSY
GGFLGL
CQCRRK
1
a
B
+
+
+
+
+
+
+
12
2
7.
0
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
2
a
A
+
+
+
>9
+
+
+
12
3
7.
1
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
3
a
C
+
+
+
<2
+
+
+
12
2
7.
0
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
4
a
D
+
+
+
<2
+
+
+
12
1
7.
0
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
5
a
S
E
C
+
+
+
+
+
10
4
6.
8
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
6
a
X
+
+
+
+
+
+
25
7.
7
+
+
+
+
+
+
+
+
+
+
+
+
+
19
b
+
+
+
+
25
7.
7
+
+
+
+
+
+
+
+
+
+
7
a
Y
+
+
+
+
+
+
28
5.
9
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
12
b
+
+
+
+
+
+
28
5.
9
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
8
a
Z
+
+
+
+
+
+
30
6.
1
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
3
b
+
+
+
+
+
+
30
6.
1
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
9
a
S
+
+
+
+
18
5.
9
+
+
+
+
+
+
+
+
+
+
+
+
+
17
b
+
+
+
18
5.
9
+
+
+
+
+
+
+
+
+
+
+
+
2
b
+
+
+
+
+
+
49
6.
4
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
16
b
+
+
+
+
+
+
49
6.
4
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
4
b
+
+
+
+
+
+
24
8.
4
+
+
+
+
+
+
+
+
+
+
+
+
+
+
5
b
+
+
+
11
4.
4
+
+
+
+
+
+
7
b
+
+
+
+
22
8.
9
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
11
b
>9
+
+
17
6.
1
+
+
+
+
+
+
+
+
+
+
+
+
+
14
b
+
+
>9
+
+
+
28
6.
2
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
15
b
+
>9
+
+
17
8.
8
+
+
+
+
+
+
+
+
+
+
+
A
m
in
o 
ac
id
 m
ot
ifs
 fo
r 
ot
he
r 
m
od
ifi
ca
tio
ns
P
K
C
C
K
2
G
ly
co
sy
la
tio
n
M
yr
is
ty
la
tio
n
Receptor
M
w
 
K
D
a 
   
    p
I 
A
m
in
o 
ac
id
 m
ot
ifs
 fo
r 
ph
os
ph
or
yl
at
io
n
SEA domain
Signal peptide
ERα interaction
Ligand
Isoform 
Alias
TM
VNTR
Source
310
Strawbridge et al
Biomarker Insights 2008:3 
Signal peptides
Protein sequences from both SwissProt (set a) and 
the HPA (set b) were analyzed. Signal peptides 
were predicted for the primary sequences of all 
variants in both sets (Bendtsen et al. 2004) and are 
present in the N terminal sequence (Fig. 4b). The 
signal peptide sequence reported previously 
(Baruch et al. 1997) is distorted in some variants, 
with 2 (set a), 11, 14 and 15 (set b) having a stretch 
of 9 amino acids inserted into the signal peptide 
(as a result of the SNP in exon 2 analyzed here) 
where as variants 3 and 4 (set a) are lacking 1 
threonine and 2 valine residues. All other variants 
have the complete signal peptide.
Secreted vs membrane tethered variants
A SEA domain was predicted for most variants 
(Falquet et al. 2002), with the exception of 5, 7, 
11, 15 and 19 (set b). However, searching the pri-
mary amino acid sequence of MUC1-C (Fig. 4b) 
of each isoform for the SEA autocatalytic cleavage 
motif (Palmai-Pallag et al. 2005) indicates that 
while most predictions are correct, MUC1/5, 
9 (set a) and 17 (set b) do not have the consensus 
sequence. MUC1/19 (set b) has part of the consen-
sus sequence, but as the fi rst 2 residues of the motif 
are altered, it may not be functional (Palmai-Pallag 
et al. 2005).
Interactions
The motif conferring interaction with β catenin (Li 
et al. 1998) is present in the cytoplasmic domain 
(Fig. 4a), and is present in all but MUC1/5 (both 
sets). Variant 5 (both sets) are the only variants 
lacking the domain required for interaction with 
ERα (Wei et al. 2006).
Phosphorylation
Part of the cytoplasmic domain is common to all 
“membrane-tethered” variants (i.e. those contain-
ing a transmembrane domain), and there is further 
homology between some variants. The potential 
for cytoplasmic domain phosphorylation (as deter-
mined by manually checking the primary sequence 
for known motifs) by GSK3β, Abl and Src does 
not appear to vary between the variants, as 
demonstrated by Figure 4b, with only variants 
5 (both sets) lacking these sites. Predicted 
phosphorylation by PKC and CK2 however 
demonstrates differences between the variants 
(Table 3). Of note, there are phosphorylation sites 
unique to variants 4 (set a) and 7 (set b).
Post-translational modifi cations
Interest in post translational modifi cations has 
mainly been focused on addition of glycosyl side 
chains, however many other modifi cations are 
likely. MUC1 variants 1–4 (set a), 2 and 6 (set b) 
are predicted to contain a proline-rich domain of 
852 residues and 6 amino acids downstream, a 
serine-rich domain of 97 residues (Falquet et al. 
2002). This region encompasses the VNTR. The 
lengths of the VNTRs of MUC1/3 and 4 (set a) 
have not been reported. Given the number of 
modifi cations possible in the VNTR the length of 
this region is likely to be very important for 
MTPGTQSPFFLLLLLTVLT [ATTAPKPAT] VVTGSGHASSTPGGEKETSATQRSSVPSSTEKNA…
…I KFRPG/ SVVVQLTLAFREGTINVHDVETQFNQYKTEAASRYNLTISDVSVSDVPFPFSAQSGAGVPGWG
IALLVLVCVLVALAIVYLIALAVCQCRRKNYGQLDIFPARDTYHPMSEY  [PTYHTHGRYVPPSSTDRSPYE
KVSAGNGGSSLS YTNP] AVAAASANL
A A B
C
Figure 4a. Conservation of MUC1 N terminal (MUC1-N) sequence. The sequence common to all variants is underlined. The signal peptide 
is the fi rst 21 residues, inside of which the novel 9 aa [square brackets] are inserted as a result of the SNP (G or variant allele) in exon 2. 
The amino acids lacking from MUC1/3 and 4 (set a) are highlighted. A stretch of a further 10aa is present in all variants except MUC1/4 
(shown in bold italics). Continuation of the amino acid sequence is denoted by….
Figure 4b. Partial protein sequence of MUC1 C terminal (MUC1-C), indicating predicted motifs. The binding site for β catenin is shown in 
bold, the SEA cleavage auto-catalytic domain is highlighted, with/indicating the residues between which cleavage occurs. Phosphorylation 
sites are indicated by larger font and arrows, with those targeted by GSK3β denoted A, Src denoted B and c-Abl denoted C. The sequence 
for palmitylation is shown in bold italics. The sequence common to all membrane-tethered variants (thus excluding isoform 5) is underlined. 
The ERα interaction domain is enclosed in [square brackets]. Continuation of the amino acid sequence is denoted by….
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function. MUC1/5 (set a) also contains these two 
domains, but with the order inverted, and while the 
proline-rich domain is the same length, the serine-
rich domain is only 47 amino acids long.
A potential motif for palmitylation (Kinlough 
et al. 2006) is found in the cytoplasmic region 
(Fig. 4b and Table 3), thus is predicted for all vari-
ants except MUC1/5 (both sets).
Glycosylation of MUC1 variants is dependent 
on the glycosyl transferases in the cell, however 
primary sequence analysis does indicate potential 
sites for attachment. Most side chains are added to 
the VNTR. Each repeat of the VNTR has the 
potential for 5 glycosyl modifi cations. Variants 
6–9 (set a) and most of set b variants do not contain 
the repeats characteristic of mucins, thus are 
unlikely to be modified to the same extent. 
A variety of modifi cation sites are predicted for 
all variants of MUC1 (Table 3). Potential myri-
stylation sites indicate another modifi cation, which 
all membrane-tethered variants share (Table 3). 
Of note, variants 15 and 7 (set b) have unique 
modifications sites, for glycosylation and 
myristylation respectively. Patterns of possible 
sialylation modifi cations may have similarities 
with those seen in glycosylation, in that the VNTR 
is the primary site for such additions.
Discussion
The results presented here demonstrate, for the fi rst 
time, a signifi cantly reduced frequency in blood 
DNA of the MUC1 3506G allele in hereditary 
prostate cancer compared to population, BPH and 
sporadic prostate cancer samples. The same 3506G 
allele is subject to LOH in prostate cancer samples 
compared to matched blood samples. Differential 
expression of MUC1 variants 1 and 2 is thus impli-
cated in prostate cancer. Loss of the G allele leads 
to a switch in expression from both MUC1/1 and 
MUC1/2 to exclusively MUC1/2, thus a protein 
with an intact signal sequence and shorter VNTR. 
A shorter VNTR may lead to a decreased protective 
function of this Mucin on the normal prostatic 
epithelial cell. Moreover, as motifs for PTMs are 
mainly present in the VNTR, the length of VNTR 
may theoretically have a multitude of effects on 
protein function. Due to the limited size of the 
sample set, independent validation is required. 
However, this fi nding is important as proof of 
principle, given that many association studies focus 
on blood DNA rather than on the tumor DNA.
Diagnostic and prognostic use of differentially 
expressed MUC1 variants has been reported for 
ovarian and breast cancers (Obermair et al. 2002; 
Schmid et al. 2002). As yet, this has not been 
addressed in prostate cancer. Our genotyping of 
matched tumor and blood samples indicates that 
isoform differences are likely equally important in 
prostate cancer. For example, the SNP per se may 
not be critical for function, as it does not alter the 
encoded amino acid. The functional difference is 
likely to stem from the associated VNTR lengths 
and potentially from the altered signal peptide 
sequence caused by the effect of the SNP on splic-
ing. The signifi cant reduction in frequency of the 
G allele of MUC1 in hereditary prostate cancer 
compared to the general population, BPH and 
sporadic prostate cancer, and the trend of reduction 
of the G allele in sporadic prostate cancer compared 
to the general population and BPH is intriguing 
and worth further investigation. The infl uence of 
different environmental exposures acting upon the 
hereditary prostate cancer and general populations 
compared to the sporadic prostate cancer and BPH 
subjects can not be ruled out.
MUC1 is a complex gene from which a number 
of variants can potentially be spliced with further 
complex PTMs. This makes it diffi cult to pinpoint 
the functional signifi cance of the allelic variation 
of the SNP presented here (rs4072037). Therefore 
we have analysed in silico predictions of MUC1 
variants. The potential for differences between the 
variants has not previously been assessed. Most of 
the variants are in silico translations of predicted 
mRNA splicing/open reading frames. Only variant 
7 (set a) is reported to be specific to cancer 
(Obermair et al. 2002), while some are reportedly 
differentially regulated between normal and 
malignant tissue. The domains and sites for PTMs 
predicted are theoretical, thus biological evidence 
of their importance for the function of these vari-
ants is still required. However, this analysis pro-
vides insight into differences between the variants 
which may be functionally relevant.
A signaling role for MUC1 has been proposed. 
MUC1-C has been shown to colocalize with both 
ERα and P53 (Wei et al. 2005; Wei et al. 2006), 
and infl uences stability or transcriptional activity 
of its binding partner. Sub-cellular localization of 
the protein is likely to determine interactions of 
this manner.
The implications of the differences in MUC1 
signal peptides are unknown. Inserting or losing 
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amino acids may render the sequence inactive, or 
may enhance its function. It would be interesting 
to elucidate whether there are differences in pro-
cessing effi ciency or sub-cellular localization as a 
result of the variations in this region. Variants lack-
ing the transmembrane domain will not, unlike the 
classical mucin, be inserted into the membrane, 
however whether they are secreted, degraded or 
remain in the cytosol where it might be more read-
ily available for signaling, is not yet known. Vari-
ants which lack the TM domain yet contain a 
complete signal peptide (variants 9 (set a), 11 and 
17 (set b)) may be secreted rather than incorporated 
into the cell membrane. This possibility is intrigu-
ing as the only isoform confi rmed to be secreted 
(variant 5 (set a)) contains a VNTR. The absence 
of the VNTR from variants is likely to infl uence 
their steric barrier function the most, and may 
infl uence ligand-receptor-like interactions between 
MUC1-N and MUC1-C fragments and potentially 
signaling mechanisms. Due to the SEA domain, 
most variants are potentially able to give rise to a 
soluble extra-cellular domain. As MUC1/5 (set a) 
is a secreted isoform the lack of the SEA domain 
is unsurprising, and may suggest that isoform 9 
(set a) may also be secreted. Variants which give 
rise to extra cellular fragments or are secreted may 
function as ligands for the membrane tethered 
potential receptors.
Differences in phosphorylation status of the 
cytoplasmic domain may determine signaling 
pathways utilized by the different variants. In par-
ticular the presence of PKC phosphorylation sites 
unique to variants 6 (set a), 7 and 19 (set b) are of 
interest, in light of an association between PKC 
phosphorylation and anchorage independent 
growth (Thompson et al. 2006). Likewise, a CK2 
phosphorylation site unique to variants 4 (set a) 
and 7 (set b) could alter signaling. Thus, the vari-
ants may differ in their oncogenic potentials. Fur-
ther research into the mechanisms and specifi city 
of modifi cations and their association with progres-
sion is awaited with interest.
Most studies of MUC1 focus on the roles which 
occur by virtue of their VNTR domains, such as 
adhesion, mucus production and barrier function. 
Given the importance of the VNTR domain, it is 
interesting that the variants lacking this domain 
also contain the SEA site, implying that they too 
may give rise to soluble extra cellular fragments. 
These variants would give rise to very short extra 
cellular fragments as well as transmembrane frag-
ments. How the two fragments transduce signals 
between the exterior and interior cellular environ-
ment is not clear. For example, ligand-receptor-like 
interactions between secreted and transmembrane 
MUC1 variants which result in phosphorylation of 
the MUC1/6 tail have been reported (Baruch et al. 
1999; Obermair et al. 2002). This poses the ques-
tions: is it only the variants which lack a VNTR 
which are able to act as receptors, or do the trans-
membrane fragments of all variants have this func-
tion? Similarly, do all extra cellular fragments or 
variants have potential as ligands? The differences 
in the variants ability to form either ligands or 
receptors and specifi city of potential interactions 
add another level of complexity to functions of 
MUC1. It is feasible that the relative abundance at 
the cell surface of the different variants and com-
petition between variants may determine the result-
ing signals.
That both under and over expression of MUC1 
is associated with prostate cancer death (Andren 
et al. 2007) suggests that the level of VNTR-
containing MUC1 variants is regulated in normal 
cells to maintain a precise level. However, the 
possibility that variations in expression of non-
VNTR-containing variants may determine tumor-
igenic potential can not be excluded. Regulation 
of glycosylation and other modifications is a 
dynamic process (Julian et al. 2002) and may 
determine the adhesive properties of the molecule 
and thus it’s ability to interact with other cell types. 
In addition, a heavily glycosylated VNTR would 
provide a mesh which may store growth factors 
and minimize immune or pathogen interactions 
with the cell membrane. The study reporting an 
association between glycosylation and angiogen-
esis but not PSA level or Gleason grade (Papado-
poulos et al. 2001) suggests that MUC1 can 
indirectly (in this case via neovascularization) 
infl uence tumor growth. Further, it was previously 
reported that sialyated MUC1 interrupts cell-cell 
adhesion, but removal of sialyation restored adhe-
sion (Wesseling et al. 1996), thus the modifi cations 
are functionally relevant.
Table 4 summarizes the variants likely to have 
been detected by the different antibodies in the 
immunohistochemistry studies reported to date of 
MUC1 expression in prostate cancer. The conclu-
sions of these studies are thus limited to the variants 
detected by each antibody. Results of these studies 
have been inconclusive or contradictory and only 
one addressed the problem of multiple variants, if 
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only briefl y. Furthermore, contradictory results in 
prostate cancer cell lines have also been observed 
when PC3, DU145 and LNCAP (or a sub culture, 
LNCaP LN3) were analyzed, with either differential 
or no expression observed (O’Connor et al. 2005), 
compared to high levels of over expression in all 
cell lines (Cozzi et al. 2005). The specifi c epitopes 
recognized by some antibodies used are unclear 
and may be part of the reason for the disparity in 
the results between studies. Antibodies which dis-
criminate between the variants are required for 
reliable assay of protein expression. Another reason 
for contradictions may be the presence of function-
ally different variants, so that measurement of total 
MUC1 expression may not be conclusive.
Most studies have assessed expression of 
MUC1 by targeting antibodies to the VNTR, thus 
fail to detect expression of 4 of 9 MUC1 set a (and 
all of set b) variants. Indeed, the modifi cations 
added to the VNTR are highly variable and 
dynamic, thus a negative result when using an 
antibody which recognizes this region may be 
misleading, as variations in modifi cation patterns 
(such as glycosylation) are likely to alter binding 
specifi city. In addition, the VNTR can be extensive, 
so the question remains as to whether dense stain-
ing of a tissue sample refl ects antibody molecules 
binding to multiple distinct MUC1 molecules, or 
many antibody molecules binding to the VNTR of 
a single MUC1 peptide.
We believe that the value of assessing varia-
tions in isoform expression has, so far, been under 
appreciated and methods to date lack standardiza-
tion which would allow for meta-analyses of 
Table 4. Summary of MUC1 antibodies used in studies of prostate cancer (PubMed search terms “MUC1, 
expression, prostate, cancer”).
Antibodies Isoforms Epitope Clonality References
139H2 N/A N/A mab (Ho et al. 1993)
214D4 1,2,3,4,5 VNTR mab (O’Connor et al. 2005)
B27.29 1,2,3,4,5 VNTR/hyper mab (Kirschenbaum et al. 
1999; Schut et al. 2003; 
Burke et al. 2006)
BC2 1,2,3,4,5* core/hypo mab (Burke et al. 2006)
BrE3 1,2,3,4,5* core/hypo N/A (Burke et al. 2006)
C595 1,2,3,4,5 VNTR mab (Mitchell et al. 2002; 
Cozzi et al. 2005)
CT-1 1,2,3,4,6,7,8 cytoplasmic N/A (O’Connor et al. 2005)
DF3 1,2,3,4,5,6,7,8,9 N terminal mab (Ho et al. 1993)
EMA 1,2,3,4,5* core/hypo N/A (Burke et al. 2006)
H23 1,2,3,4,5 VNTR N/A (Legrier et al. 2004)
HMFG-1 1,2,3,4,5 VNTR/hyper mab (Mitchell et al. 2002; 
Schut et al. 2003; Burke 
et al. 2006)
HMFG2 1,2,3,4,5 VNTR mab (Mitchell et al. 2002; 
Zhang et al. 2004; Singh 
et al. 2006)
M8 N/A N/A N/A (Legrier et al. 2004)
MoAb 1,2,3,4,5# glycosylated mab (Papadopoulos et al. 
2001)
MY.1E12 1,2,3,4,5# sialyated mab (Arai et al. 2005)
NCL core 1,2,3,4,5 core/hyper N/A (Burke et al. 2006)
sc7313 1,2,3,4,5 VNTR mab (Lapointe et al. 2004; 
Andren et al. 2007)
SM3 1,2,3,4,5 VNTR/hypo mab (Mitchell et al. 2002; 
Burke et al. 2006)
VU4H5 1,2,3,4,5 VNTR mab (Andren et al. 2007)
*Assuming core refers to the non-VNTR region of the extracellular domain. #Most side chains are added to the VNTR. mab monoclonal 
antibody, pab polyclonal antibody, hypo hypoglycosylated, hyper hyperglycosylated N/A not available.
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results. Predictions of differences between the 
MUC1 variants suggest distinct functions, of as 
yet unknown importance. The actual expression 
of in silico predicted variants needs to be con-
fi rmed and their biological functions determined 
experimentally. Further research into the mecha-
nisms and specifi city of PTMs and their associa-
tion with progression is awaited with interest. 
Improvement in methods for determining isoform 
expression patterns and functions could thus yield 
valuable information. The fi nding described in this 
report of a prostate cancer-associated functionally 
relevant variation supports the notion that the 
MUC1 gene may be a useful marker for prostate 
and other cancers.
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